DAVID C HASTINGS
CIK 1237401 · Chief Financial Officer · last filed 2026-01-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.24M
Companies
6
Total Filings
51
Lifetime Open-Market Net
-$25.66M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRVI | Chief Financial Officer | — | $18.43 | — | $0 | 1 | 2026-01-12 |
| SCYX | Director | 8,648 | $3.63 | $31.4K | $55.0K | 16 | 2025-06-30 |
| ABUS | Chief Financial Officer | 249,824 | $4.41 | $1.10M | -$95.0K | 9 | 2025-02-19 |
| Entasis Therapeutics Holdings Inc. (ETTX) Delisted | Director | 0 | $2.19 | $0 | $0 | 7 | 2022-07-11 |
| Unilife Corp (UNIS) Delisted | See Remarks | 30,000 | — | — | $0 | 2 | 2017-01-30 |
| INCY | Chief Financial Officer | 8,500 | $129.93 | $1.10M | -$25.62M | 15 | 2014-02-18 |
Recent Filings · Page 3 of 6
51 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-07-08 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2020-02-19 | ABUS | Grant (A) | — | $0 | EDGAR |
| 2019-06-21 | Entasis Therapeutics Holdings Inc. (ETTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-20 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2019-03-05 | ABUS | Grant (A) | — | $0 | EDGAR |
| 2019-01-22 | Entasis Therapeutics Holdings Inc. (ETTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-01-04 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2018-06-21 | ABUS | Grant (A) | — | $0 | EDGAR |
| 2018-03-12 | SCYX | Buy (P) | +11,834 | $20.0K | EDGAR |
| 2018-01-04 | SCYX | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.